

April 09, 2019

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Re: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is in continuation to our letters dated February 26, 2019 and February 27, 2019 intimating about the One time settlement ("OTS") with the consortium of lenders of the Company.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would now like to inform you that the Company has done OTS with the consortium lenders and details of the same as required are as under:

S. No.	Particulars	Description
1.	Reasons for opting for OTS	In order to resolve the current debt position of the Company.
2.	Brief summary of the OTS	All consortium lenders have approved the bilateral OTS at 65% of their outstanding debts.

We request you to kindly bring the above information to the notice of your members.

Thanking you,

Sincerely yours,

For Panacea Biotec Ltd.

Vinod Goel

Group CFO and Head Legal

& Company Secretary

B1 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9070